 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678910» |
- Fetroja (cefiderocol) / Shionogi
Genomic Features Associated with Non-susceptibility to Cefiderocol in Pseudomonas aeruginosa and Cross-resistance to Novel ?-lactam/?-lactamase Inhibitors in the Prospective Observational Pseudomonas (POP) study (404 AB) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_846;
- | Journal, Gram negative: Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy. (Pubmed Central) - Aug 26, 2024
Based on confirmed susceptibility rates and reported ICU prevalence of multiple Gram-negative species, cefiderocol showed a higher predicted therapeutic coverage and utility in ICUs compared with comparator beta-lactam-beta-lactamase inhibitor antibiotics. Cefiderocol may be a promising early treatment option for patients at high risk of carbapenem-resistant Gram-negative bacterial infections in the ICU.
- | imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Identification of a novel Providencia species showing multi-drug-resistant in three patients with hospital-acquired infection. (Pubmed Central) - Aug 4, 2024
is proposed. The type strain is CRE-3FA-0001T =CCTCC AB 2023186T=KCTC 8373T.
- | imipenem/relebactam / Merck (MSD)
Journal: Phage Therapy in a Burn Patient Colonized with Extensively Drug-Resistant Pseudomonas aeruginosa Responsible for Relapsing Ventilator-Associated Pneumonia and Bacteriemia. (Pubmed Central) - Jul 31, 2024
We report here the case of a severely burned patient who experienced relapsing ventilator-associated pneumonia associated with skin graft infection and bacteremia due to extensively drug-resistant P. aeruginosa. The patient was successfully treated with personalized nebulized and intravenous phage therapy in combination with immunostimulation (interferon-?) and last-resort antimicrobial therapy (imipenem-relebactam).
- | cefepime/zidebactam IV (WCK 5222) / Wockhardt
Journal: Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through ?-lactam-enhancer-mechanism-based cefepime/zidebactam. (Pubmed Central) - Jul 28, 2024
This study shows that the novel ?-lactam enhancer approach enables cefepime/zidebactam to overcome both non-enzymatic and enzymatic resistance mechanisms associated with a challenging panel of P. aeruginosa. This study highlights that the ?-lactam enhancer mechanism is a promising alternative to the conventional ?-lactam/?-lactamase inhibitor approach in combating ever-evolving MDR P. aeruginosa.
- || Review, Journal, Gram negative: Novel Antibiotics for Gram-Negative Nosocomial Pneumonia. (Pubmed Central) - Jul 27, 2024
We critically present data for the pharmacokinetics/pharmacodynamics, the in vitro spectrum of antimicrobial activity and resistance, and in vivo data for their clinical and microbiological efficacy in trials. Where possible, available data are summarized specifically in patients with nosocomial pneumonia, as this cohort may exhibit 'critical illness' physiology that affects drug efficacy.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini
Journal: Non-KPC Attributes of Newer ?-lactamase/?-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosa. (Pubmed Central) - Jul 19, 2024
It is critical for clinicians to understand the unique spectra of these BL/BLIs with respect to non-KPC CRO. In Part 1of this two-part series, we describe the non-KPC attributes of the newer BL/BLIs with a focus on utility against Enterobacterales and Pseudomonas aeruginosa.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Resistance to ceftazidime-avibactam and other new ?-lactams in Pseudomonas aeruginosa clinical isolates: a multi-center surveillance study. (Pubmed Central) - Jun 27, 2024
Among non-?-lactams, colistin and amikacin were active against 100% and 85.8% of isolates respectively...With this work, we report that CZA represents a highly active antipseudomonal ?-lactam compound (after cefiderocol), and that metallo-?-lactamases (VIM-type) and extended-spectrum ?-lactamases (GES and PER-type) production is the major factor underlying CZA resistance in isolates from Southern Italian hospitals. In addition, we reported that such resistance mechanisms were mainly carried by the international high-risk clones ST111 and ST235.
- | Fetroja (cefiderocol) / Shionogi
Preclinical, Journal: In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recent?-lactam/?-lactamase inhibitor combinations. (Pubmed Central) - Jun 21, 2024
Cefiderocol susceptibility was higher than approved ?-lactam/?-lactamase inhibitor combinations and largely comparable to cefepime-taniborbactam and aztreonam-avibactam against all Enterobacterales (98.1% vs 78.1%-?97.4% and 98.7%-99.1%, respectively) and Enterobacterales resistant to meropenem (n = 148, including 125 Klebsiella spp.; 87.8% vs 0%-71.6% and 93.2%-98.6%, respectively), ?-lactam/?-lactamase inhibitor combinations (66.7%-?92.1% vs 0%-?88.1% and 66.7%-97.9%, respectively), and to both meropenem and ?-?lactam/?-lactamase inhibitor combinations (61.9%-65.9% vs 0%-?20.5% and 76.2%-97.7%, respectively)...Early susceptibility testing of cefiderocol in parallel with ?-lactam/?-lactamase inhibitor combinations will allow patients to receive the most appropriate treatment option(s) available in a timely manner. This is particularly important when options are more limited, such as against metallo-?-lactamase-producing Enterobacterales.
- | cefepime hydrochloride / Generic mfg.
Journal: Activity of cefepime, carbapenems and new ?-lactam/?-lactamase inhibitor combinations on Enterobacter cloacae complex and Klebsiella aerogenes in Spain (SMART 2016-2022). (Pubmed Central) - Jun 7, 2024
In contrast, differences have been found in the case of cefepime, showing more activity against K. aerogenes than E. cloacae complex. These results are useful for antimicrobial stewardship programmes and for the implementation of local and national guidelines.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini
Journal: Epidemiology and antimicrobial susceptibility profiles of Enterobacterales causing bloodstream infections before and during COVID-19 pandemic: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2018-2021. (Pubmed Central) - Jun 6, 2024
The COVID-19 pandemic appears to be associated with a general decrease in antimicrobial susceptibility rates among Enterobacterales causing BSIs in Taiwan. Continuous surveillance is crucial to monitor antimicrobial resistance during the pandemic and in the future.
- | Fetroja (cefiderocol) / Shionogi
Preclinical, Journal: In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain. (Pubmed Central) - Jun 2, 2024
Continuous surveillance is crucial to monitor antimicrobial resistance during the pandemic and in the future. Our results position cefiderocol as a therapeutic option in pwCF infected with P. aeruginosa resistant to most recent ?-lactam/?-lactamase inhibitor combinations.
- || Review, Gram negative: Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review. (Pubmed Central) - May 27, 2024
The present review aims to highlight these six antibiotic agents, which have brought hope to clinicians during the past decade, discussing general properties of these substances, as well as mechanisms and patterns of resistance, while also providing a short overview on further directions in the field. https://www.crd.york.ac.uk/prospero/#searchadvanced, Identifier CRD42024505832.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Journal, Gram negative: Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico-SMART 2017-2021. (Pubmed Central) - May 27, 2024
Almost all imipenem/relebactam-non-susceptible E. coli and K. pneumoniae carried MBL or OXA-48-like carbapenemases, whereas among imipenem/relebactam-non-susceptible P. aeruginosa, 56% carried MBL or GES carbapenemases. Ceftolozane/tazobactam and imipenem/relebactam may provide treatment options for patients infected with ?-lactam-non-susceptible Gram-negative bacilli, excluding isolates carrying an MBL- or OXA-48-like carbapenemase.
- | Preclinical, Journal: Comparative In Vitro Activity of Ceftazidime-Avibactam, Imipenem-Relebactam, and Meropenem-Vaborbactam against Carbapenem-Resistant Clinical Isolates of Klebsiella pneumoniae and Pseudomonas aeruginosa. (Pubmed Central) - May 24, 2024
Source of infection and co-infection did not significantly influence antimicrobial activity for IRL and CZA; none of the CRPA isolates from co-infected patients were susceptible to MVB. Our results suggest that novel ?-lactam agents with antipseudomonal activity and stability against carbapenemases, such as IRL and CZA, offer potential monotherapy options for the treatment of co-infection involving both CRKP and CRPA, but not MVB.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Journal: Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021. (Pubmed Central) - May 22, 2024
Our results suggest that novel ?-lactam agents with antipseudomonal activity and stability against carbapenemases, such as IRL and CZA, offer potential monotherapy options for the treatment of co-infection involving both CRKP and CRPA, but not MVB. We conclude that C/T and IMI/REL may provide viable treatment options for many patients from Greece and Italy.
- | relebactam (MK-7655) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam. (Pubmed Central) - Apr 30, 2024
The dose-escalation test of new BLIs demonstrated that increasing doses of new BLIs corresponded to increased susceptibility to BLs. Taken together, this study illustrates the excellent activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales and suggests further investigation into high-concentration regimens for potentially non-susceptible clinical isolates.
- | Preclinical, Journal: In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex. (Pubmed Central) - Apr 22, 2024
Cefiderocol could be considered as a potential new option for multidrug resistant infections. Tetracyclines had the best in vitro activity of all antibiotics evaluated.
- | Fetroja (cefiderocol) / Shionogi
Preclinical, Journal: In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent ?-lactam/?-lactamase inhibitor combinations. (Pubmed Central) - Apr 8, 2024
inhibitor combinations against P. aeruginosa (98.9% vs 83.3%-91.4%), and P. ?aeruginosa resistant to meropenem (n = 139; 97.8% vs 12.2%-59.7%), ?-lactam/?-lactamase inhibitor combinations (93.6%-98.1% vs 10.7%-71.8%), and both meropenem and ceftazidime-avibactam (96.7% vs 5.0%-??45.0%) or ?ceftolozane-tazobactam (98.4% vs 8.1%-54.8%), respectively...(n = 227; 85.0% and 93.8%) but lower against sulbactam-durlobactam- (n ?= 15; 13.3%) and cefiderocol- (n = 38; 65.8%) resistant isolates, respectively...and indicate how early susceptibility testing of cefiderocol in parallel with ?-lactam/?-lactamase inhibitor combinations will allow clinicians to choose the effective treatment(s) from all available options. This is particularly important as current treatment options against non-fermenters are limited.
- | Emblaveo (aztreonam/avibactam) / Pfizer, AbbVie
Journal: Activity of Aztreonam-Avibactam against Enterobacterales Resistant to Recently Approved Beta-Lactamase Inhibitor Combinations Collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022). (Pubmed Central) - Apr 8, 2024
This is particularly important as current treatment options against non-fermenters are limited. Aztreonam-avibactam demonstrated potent activity against CRE isolates resistant to ceftazidime-avibactam, meropenem-vaborbactam, and/or imipenem-relebactam independent of the carbapenemase produced.
- | relebactam (MK-7655) / Merck (MSD)
Preclinical, Journal: Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-?-Lactamase-Producing Enterobacterales Infections-In Vitro Susceptibility Testing. (Pubmed Central) - Mar 28, 2024
We investigated 21 NDM isolates-including Klebsiella pneumoniae, Escherichia coli, and Citrobacter freundii-which are simultaneously resistant to aztreonam, ceftazidime/avibactam, imipenem/relebactam, and meropenem/vaborbactam...The most effective combination was aztreonam/avibactam, active in 80.95% strains, while combinations with relebactam and vaborbactam were effective in 61.90% and 47.62%, respectively...However, combinations with other inhibitors should not be rejected in advance because we identified strain susceptible only to tested combinations with inhibitors other than avibactam. Standardization committees should, as soon as possible, develop official methodology for antimicrobial susceptibility testing for aztreonam with ?-lactamase inhibitors.
- || Review, Journal: Antimicrobial and Diagnostic Stewardship of the Novel ?-Lactam/?-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and Pseudomonas aeruginosa. (Pubmed Central) - Mar 27, 2024
Finally, in order to address the absence of a standardized approach to using the novel BL/BLIs, we propose a diagnostic and therapeutic algorithm, which can be modified based on local epidemiological criteria. This framework could also be expanded to incorporate other new antimicrobials, such as cefiderocol, or currently unavailable BL/BLIs such as aztreonam/avibactam and cefepime/taniborbactam.
- || imipenem/relebactam / Merck (MSD)
PK/PD data, Journal: Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation. (Pubmed Central) - Mar 22, 2024
This framework could also be expanded to incorporate other new antimicrobials, such as cefiderocol, or currently unavailable BL/BLIs such as aztreonam/avibactam and cefepime/taniborbactam. Imipenem/cilastatin/relebactam dosed according to package insert in patients supported on ECMO is predicted to achieve exposures sufficient to treat susceptible Gram-negative isolates, including Pseudomonas aeruginosa.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Rates of resistance and heteroresistance to newer ?-lactam/?-lactamase inhibitors for carbapenem-resistant Enterobacterales. (Pubmed Central) - Mar 22, 2024
Twenty-four percent of CRE isolates tested were either resistant or heteroresistant (HR) to newer BL/BLIs, with an overall decrease of ?10% susceptibility over 6?years. While newer BL/BLIs remain active against most CRE, these findings support the need for ongoing antibiotic stewardship and a better understanding of the clinical implications of HR in CRE.
- | imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Hidden threats in the plastisphere: Carbapenemase-producing Enterobacterales colonizing microplastics in river water. (Pubmed Central) - Mar 20, 2024
While newer BL/BLIs remain active against most CRE, these findings support the need for ongoing antibiotic stewardship and a better understanding of the clinical implications of HR in CRE. Uncommon phenotypes of resistance to imipenem/relebactam (n
- imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Antimicrobial Susceptibility of Klebsiella Pneumoniae Clinical Isolates From the Lower Respiratory Tract Infection During the COVID-19 Pandemic in Brazil (SMART 2020-2021) () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1822;
This study highlights an elevated prevalence of KPC-producing K. pneumoniae from the LRTI in Brazil, which underscores the urgent need to implement strategies to combat antimicrobial resistance. Furthermore, IMR is a new antibiotic that maintains high in vitro activity even in resistant isolates and can serve as another important treatment option for pneumonia caused by K. pneumoniae .
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: Assessing the in vivo impact of novel ?-lactamase inhibitors on the efficacy of their partner ?-lactams against serine carbapenemase-producing Pseudomonas aeruginosa using human-simulated exposures. (Pubmed Central) - Mar 4, 2024
The activity of meropenem/vaborbactam was variable, suggesting this may be an inferior treatment option in this setting. Further studies to evaluate clinical outcomes in GES- and KPC-producing P. aeruginosa are warranted given their increasing prevalence worldwide.
- | Journal: Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum ?-lactamases. (Pubmed Central) - Feb 28, 2024
While imipenem-relebactam showed a similar activity regardless of the PBP3 background, susceptibility to other molecules tested was affected at various levels. This was particularly the case for ceftazidime-avibactam, aztreonam-avibactam, and cefepime-taniborbactam.
- | imipenem/relebactam / Merck (MSD)
Journal, Gram negative: Structure Guided Discovery of Novel Pan Metallo-?-Lactamase Inhibitors with Improved Gram-Negative Bacterial Cell Penetration. (Pubmed Central) - Feb 22, 2024
Herein, we describe our work to improve the GN coverage spectrum in combination with imipenem and relebactam...In addition, pharmacokinetics and nonclinical safety profiles were investigated for select compounds. Key findings from this drug discovery campaign laid the foundation for further lead optimization toward identification of preclinical candidates.
- || PK/PD data, Review, Journal, Gram negative: New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Liver Transplantation: Clinical Perspectives, Toxicity, and PK/PD Properties. (Pubmed Central) - Feb 20, 2024
Overall, studies on the safety and optimal employment of these drugs in liver transplant recipients are limited and especially needed. Nevertheless, these pharmaceuticals have undeniably enhanced therapeutic options for infected liver transplant recipients.
- imipenem/relebactam / Merck (MSD)
Imipenem Pharmacokinetics/Pharmacodynamics in the Hollow Fiber Model of Mycobacterium Abscessus (San Diego Convention Center, Area L (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_6609;
Imipenem/relebactam demonstrated effectiveness in the HFS-Mab and MCE predicted 1g every 6h, infused over 2h for optimal efficacy. However, tolerability of the HFS-Mab identified dose could be an issue.
- imipenem/relebactam / Merck (MSD)
Rapid detection of imipenem/relebactam susceptibility/resistance in Pseudomonas aeruginosa (Arena 3) - Feb 1, 2024 - Abstract #ECCMID2024ECCMID_1650;
- Susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam and cefiderocol of Escherichia coli strains producing broad-spectrum (Arena 3) - Feb 1, 2024 - Abstract #ECCMID2024ECCMID_1321;
- imipenem/relebactam / Merck (MSD)
In vitro activity of imipenem/relebactam against Klebsiella pneumoniae strains producing KPC beta-lactamases (KPC-Kp) isolated in Italy in the period 2016-2018 (Arena 3) - Feb 1, 2024 - Abstract #ECCMID2024ECCMID_1317;
- imipenem/relebactam / Merck (MSD)
Susceptibility of clinically relevant Achromobacter spp. isolates collected globally to imipenem/relebactam and comparator agents: SMART 2015-2021 (Arena 2) - Feb 1, 2024 - Abstract #ECCMID2024ECCMID_807;
- | ANT3310 / Antabio
Journal, Gram negative: Meropenem-ANT3310, a unique ?-lactam-?-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii. (Pubmed Central) - Jan 30, 2024
However, tolerability of the HFS-Mab identified dose could be an issue. MEM was poorly active against A. baumannii, as were MEM-vaborbactam, ceftazidime-avibactam, aztreonam-avibactam, cefepime-taniborbactam, cefepime-zidebactam, and imipenem-relebactam (MIC values of ?32
- | Fetroja (cefiderocol) / Shionogi
Journal, Gram negative: Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives? (Pubmed Central) - Jan 29, 2024
On the other hand, imipenem-relebactam and meropenem-vaborbactam showed the highest susceptibility rates against P. aeruginosa isolates. Finally, sulbactam-durlobactam and cefiderocol combined with a BLI were the only effective options against A. baumannii tested isolates.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Moving towards a standardized definition of antimicrobial resistance: a comparison of the antimicrobial susceptibility profile of difficult-to-treat resistance (DTR) versus multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates (CANWARD, 2016-2021). (Pubmed Central) - Jan 22, 2024
Susceptibility was lower for all antimicrobials versus DTR relative to MDR isolates. Ceftazidime-avibactam, ceftolozane-tazobactam, and imipenem-relebactam susceptibility was 35.9%, 64.5%, and 47.0% for DTR isolates and 60.5%, 80.6%, and 71.5% for MDR isolates.
- || imipenem/relebactam / Merck (MSD)
Retrospective data, Review, Journal, Gram negative: Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis. (Pubmed Central) - Jan 4, 2024
The findings of this analysis show that imipenem/relebactam resistance is rare in the majority of developed countries. Given that relebactam has proven to restore the activity of imipenem against current clinical isolates, further research into imipenem/relebactam is necessary.
- | imipenem/relebactam / Merck (MSD)
Journal: Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa. (Pubmed Central) - Jan 2, 2024
Imipenem/relebactam showed excellent activity against K. pneumoniae KPC-3. The activity of imipenem/relebactam against imipenem-resistant P. aeruginosa was moderate.
- | Fetroja (cefiderocol) / Shionogi
Preclinical, Journal: In vitro activity of cefiderocol against a global collection of carbapenem-resistant Pseudomonas aeruginosa with a high level of carbapenemase diversity. (Pubmed Central) - Dec 28, 2023
Cefiderocol was highly active against MBL-producing isolates, where treatment options are limited. These data can help guide empirical therapy guidelines based on local prevalence of carbapenemase-producing P. aeruginosa or in response to rapid molecular diagnostics.
- || Review, Journal: Approaches to Testing Novel ?-Lactam and ?-Lactam Combination Agents in the Clinical Laboratory. (Pubmed Central) - Dec 23, 2023
While their introduction offers a beacon of hope, clinical microbiology laboratories must navigate the complexities of susceptibility testing for these agents due to their diverse activity profiles against specific ?-lactamases and the possibility of acquired resistance mechanisms in some bacterial isolates. This review explores the complexities of these novel antimicrobial agents detailing the intricacies of their application, providing guidance on the nuances of susceptibility testing, interpretation, and result reporting in clinical microbiology laboratories.
- | imipenem/relebactam / Merck (MSD)
Preclinical, Journal: In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis. (Pubmed Central) - Dec 17, 2023
Imipenem/relebactam, imipenem, meropenem, ceftazidime/avibactam, and ceftolozane/tazobactam susceptibilities were 77%, 55%, 58%, 90%, and 92%, respectively. Relebactam potentiates imipenem against CF P. aeruginosa by fourfold leading imipenem/relebactam to retain susceptibility against most isolates in this cohort.
- | imipenem/relebactam / Merck (MSD)
Journal: bla overexpression and bla carriage as major imipenem/relebactam resistance mechanisms in Pseudomonas aeruginosa high-risk clones ST463 and ST235, respectively, in China. (Pubmed Central) - Dec 17, 2023
In conclusion, IR-resistant CRPA isolates in China were mainly distributed in P. aeruginosa high-risk clones ST463 and ST235. The major underlying IR resistance mechanisms were bla overexpression and bla carriage.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Activity of novel ?-lactam/?-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa. (Pubmed Central) - Dec 4, 2023
Among the novel BL/BLIs, ceftazidime/avibactam displayed better in vitro activity and thus is a rational treatment option for serine carbapenemase-harbouring P. aeruginosa. While imipenem/relebactam displayed some activity, particularly against isolates with blaKPC, meropenem/vaborbactam exhibited poor activity, with MICs similar to meropenem alone.
- || Review, Journal: What are the most relevant publications in Clinical Microbiology in the last two years? (Pubmed Central) - Nov 28, 2023
This minireview describes some of the articles published in the last two years related to innovative technologies including CRISPR-Cas, surface-enhanced Raman spectroscopy, microfluidics, flow cytometry, Fourier transform infrared spectroscopy, and artificial intelligence and their application to microbiological diagnosis, molecular typing and antimicrobial susceptibility testing. In addition, some articles related to resistance to new antimicrobials (ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, and cefiderocol) are also described.
- | relebactam (MK-7655) / Merck (MSD)
Preclinical, Journal: Role of Relebactam in the Antibiotic Resistance Acquisition in Pseudomonas aeruginosa: In Vitro Study. (Pubmed Central) - Nov 24, 2023
The addition of relebactam delays the generation of resistance to imipenem and limits the cross-resistance to other beta-lactams. The clinical relevance of this phenomenon, which has the limitation that it has been performed in vitro, should be evaluated by stewardship programs in clinical practice, as it could be useful in controlling multi-drug resistance in P. aeruginosa.
- | aztreonam/avibactam (PF-06947387) / Pfizer, AbbVie, imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates. (Pubmed Central) - Nov 20, 2023
Our in vitro activity study revealed that only few antibacterial agents (including several novel agents) exhibit high antimicrobial activity toward carbapenem-resistant Klebsiella pneumoniae (CRKP) and CR-hvKP isolates. IMR and AZA may be promising therapeutic agents for the treatment of infections caused by CRKP and CR-hvKP isolates.
- | Fetroja (cefiderocol) / Shionogi
Preclinical, Journal: In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates. (Pubmed Central) - Nov 17, 2023
The results suggest that cefiderocol could be a possible treatment option for RTIs caused by Achromobacter spp. and Bcc.
- || imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Review, Journal: Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. (Pubmed Central) - Nov 8, 2023
In addition, meropenem-vaborbactam, imipenem-relebactam, and other new ?-lactam-?-lactamase inhibitor combinations have little discussion on KPC variants. This review aims to discuss the clinical characteristics, risk factors, epidemiological characteristics, antimicrobial susceptibility profiles, methods for detecting bla variants, treatment options, and future perspectives of bla variants worldwide to alert this new great public health threat.